This is a phase III, randomized, comparator-controlled, double-blind, multicenter study to evaluate lot-to-lot consistency of three lots of a PIKA Rabies Vaccine, immunogenicity and safety in healthy adults using a post-exposure prophylaxis schedule. It is also the aim of this study to evaluate non-inferiority and superiority of the PIKA Rabies Vaccine compared to the rabies vaccine comparator ChiroRab.
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Primary Immunogenicity
Timeframe: 14 days post-vaccination
Primary Immunogenicity
Timeframe: 14 days post-vaccination
Co-primary Safety(solicited AEs)
Timeframe: 7 days after each vaccination.
Co-primary Safety(unsolicited AEs)
Timeframe: From day of first vaccination through 14 days after the last vaccination
Co-primary Safety(SAEs)
Timeframe: through study completion, an average of 1 year
Co-primary Safety
Timeframe: through study completion, an average of 1 year